心肌肌球蛋白抑制剂Aficamten的循证进展与未来治疗方向-从机制探索到临床实践

王琦 ,  邹云增

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1249 -1255.

PDF (1307KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1249 -1255. DOI: 10.12092/j.issn.1009-2501.2026.09.011
综述与讲座

心肌肌球蛋白抑制剂Aficamten的循证进展与未来治疗方向-从机制探索到临床实践

作者信息 +

Evidence-based progress and future therapeutic directions of myosin inhibitor aficamten-from mechanistic exploration to clinical practice

Author information +
文章历史 +
PDF (1337K)

摘要

肥厚型心肌病(hypertrophic cardiomyopathy,HCM)是一种常见的遗传性心肌病,其中梗阻型肥厚型心肌病(obstructive hypertrophic cardiomyopathy,oHCM)患者因左心室流出道(left ventricular outflow tract,LVOT)梗阻而面临较高的心力衰竭与心律失常风险。传统药物治疗主要以缓解症状为目标,难以逆转疾病的病理生理进程。心肌肌球蛋白抑制剂(cardiac myosin inhibitors,CMIs)的出现,标志着 HCM 治疗进入了靶向干预疾病核心机制的新时代。Aficamten 凭借其独特的药代动力学特征(如较短半衰期、较低药物相互作用风险)和卓越的疗效与安全性,在多项关键临床试验中证实可显著改善 oHCM 患者的运动耐量、症状和生活质量,并展现出逆转心脏重构的潜力。本文系统综述 Aficamten 的作用机制、药理学特性、临床开发历程及其在 HCM 治疗格局中的定位,并对未来个体化治疗和疾病修饰作用的研究方向进行展望。

Abstract

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy, in which patients with the obstructive form (oHCM) face an elevated risk of heart failure and arrhythmias due to left ventricular outflow tract (LVOT) obstruction. Traditional drug therapies primarily aim to alleviate symptoms and are often unable to reverse the pathophysiological progression of the disease. The advent of cardiac myosin inhibitors (CMIs) marks the entry of HCM treatment into a new era of targeted intervention addressing the core disease mechanism. With its unique pharmacokinetic profile-such as a short half-life and low risk of drug-drug interactions-along with outstanding efficacy and safety, Aficamten has been demonstrated in multiple key clinical trials to significantly improve exercise capacity, symptoms, and quality of life in patients with oHCM, while also showing potential for reversing cardiac remodeling. This article systematically reviews the mechanism of action, pharmacological properties, clinical development history of Aficamten, and its position within the HCM treatment landscape, and offers perspectives on future research directions for personalized therapy and disease-modifying effects.

关键词

Aficamten / 心肌肌球蛋白抑制剂 / 肥厚型心肌病 / 左心室流出道梗阻 / 靶向治疗

Key words

Aficamten / cardiac myosin inhibitors / hypertrophic cardiomyopathy / left ventricular outflow tract obstruction / targeted therapy

引用本文

引用格式 ▾
王琦,邹云增. 心肌肌球蛋白抑制剂Aficamten的循证进展与未来治疗方向-从机制探索到临床实践[J]. 中国临床药理学与治疗学, 2026, 31(9): 1249-1255 DOI:10.12092/j.issn.1009-2501.2026.09.011

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Pagel PS, Hang D, Freed JK, et al. Advances in cardiovascular pharmacotherapy I cardiac myosin inhibitors[J].J Cardiothorac Vasc Anesth, 2025, 39(5): 1287-1305.

[2]

Abunada A, Shah M, Kumar A, et al. Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials[J].Front Cardiovasc Med, 2025, 11: 1477487.

[3]

Gollapudi SK, Ma W, Chakravarthy S, et al. Two classes of myosin inhibitors, para-nitroblebbistatin and mavacamten, stabilize β-cardiac myosin in different structural and functional states[J].J Mol Biol, 2021, 433(23): 167295.

[4]

唐媛媛, 唐博謇, 严晓伟, 等. 肥厚梗阻型与非梗阻型心肌病的临床特点和预后分析[J].中国临床药理学与治疗学, 2009, 14(2): 195-198.

[5]

Olivotto I, Udelson JE, Pieroni M, et al. Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments[J].Eur Heart J, 2023, 44(8): 656-667.

[6]

Ogieuhi IJ, Ajekiigbe VO, Adeyemi BA, et al. Cardiac myosin inhibitors: efficacy, safety and future directions of aficamten in hypertrophic obstructive cardiomyopathy[J].Egypt Heart J, 2025, 77(1): 61.

[7]

Mohran S, Kooiker KB, Naim A, et al. Myosin modulator Aficamten inhibits force in cardiac muscle by altering myosin's biochemical activity without changing thick filament structure[J].JACC Basic Transl Sci, 2026, 11(1): 101449.

[8]

Coats CJ, Masri A, Nassif ME, et al. Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM[J].J Am Heart Assoc, 2024, 13(15): e035993.

[9]

Pugsley MK, Hwee DT, Winters BR, et al. A characterization of the nonclinical pharmacology and toxicology of aficamten, a reversible allosteric inhibitor of cardiac myosin[J].Int J Toxicol, 2025, 44(3): 211-234.

[10]

Lim J, Kim HK.Cardiac myosin inhibitors in hypertrophic cardiomyopathy[J].J Cardiovasc Imaging, 2025, 33(1): 7.

[11]

Ramadan MM, Al-Najjar RA, Abady RS, et al. Mavacamten cardiac myosin inhibitor: clinical applications and future perspectives[J].Cureus, 2025, 17(4): e82722.

[12]

Dalo JD, Weisman ND, White CM. Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy[J].Ann Pharmacother, 2023, 57(4): 489-502.

[13]

Malik FI, Robertson LA, Armas DR, et al. A Phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants[J].JACC Basic Transl Sci, 2022, 7(8): 763-775.

[14]

Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy[J].J Med Chem, 2021, 64(19): 14142-14152.

[15]

Zhao X, Liu H, Tian W, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study[J].Front Pharmacol, 2023, 14: 1227470.

[16]

Xu D, Divanji P, Griffith A, et al. Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans[J].Pharmacol Res Perspect, 2024, 12(5): e70006.

[17]

Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J].Am Coll Cardiol, 2023, 81(1): 34-45.

[18]

Owens AT, Masri A, Abraham TP, et al. Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM Cohort 3[J].J Card Fail, 2023, 29(11): 1576-1582.

[19]

Masri A, Sherrid MV, Abraham TP, et al. Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM Trial, Cohort 4[J].J Card Fail, 2024, 30(11): 1439-1448.

[20]

Saleh D, Eskandari M, Choudhury L.Aficamten in the treatment of obstructive hypertrophic cardiomyopathy[J].Future Cardiol, 2025, 21(9): 685-691.

[21]

Garcia-Pavia P, Maron MS, Masri A, et al. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy[J].N Engl J Med, 2025, 393(10): 949-960.

[22]

Saberi S, Abraham TP, Choudhury L, et al. Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: 48-week results from FOREST-HCM[J].JACC Heart Fail, 2025, 13(8): 102496.

[23]

Sebastian SA, Padda I, Lehr EJ, et al. Aficamten: a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy[J].Am J Cardiovasc Drugs, 2023, 23(5): 519-532.

[24]

Kukowka A, Droździk M. Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy: clinical trials and future challenges[J].Biomolecules, 2025, 15(8): 1098.

[25]

Davis BJ, Volk H, Nguyen O, et al. Safety and efficacy of mavacamten and aficamten in patients with hypertrophic cardiomyopathy[J].J Am Heart Assoc, 2025, 14(6): e038758.

[26]

Hasana U, Korpal M, Haider F, et al. Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials[J].Ann Med Surg (Lond), 2025, 87(6): 3810-3818.

[27]

《心肌肌球蛋白抑制剂药物治疗专家共识》工作组, 张志玲. 心肌肌球蛋白抑制剂药物治疗专家共识[J].临床药物治疗杂志, 2026, 24(3): 1-13.

[28]

Masri A, Cardoso RN, Abraham TP, et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR Substudy[J].J Am Coll Cardiol, 2024, 84(19): 1806-1817.

[29]

Cytokinetics. Cytokinetics announces NMPA approval of MYQORZO® (aficamten) in China for patients with obstructive hypertrophic cardiomyopathy[EB/OL]. (2025-12-17)[2026-09-17].https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Announces-NMPA-Approval-of-MYQORZO-aficamten-in-China-for-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy/default.aspx.

[30]

US FDA. Myqorzo (aficamten): NDA approval[EB/OL] (2025-03-09)[2026-09-17].https://www.accessdata.fda.gov/drugsatfda_docs/appleletter/2025/219083Orig1s000ltr.pdf.

[31]

Cytokinetics. Cytokinetics announces European Commission approval of MYQORZO® (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy[EB/OL]. (2026-02-17)[2026-09-17].https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-European-Commission-Approval-of-MYQORZO-aficamten-for-the-Treatment-of-Adults-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy/default.aspx.

[32]

Masri A, Maron MS, Abraham TP, et al. Concomitant Aficamten and disopyramide in symptomatic obstructive hypertrophic cardiomyopathy[J].JACC Heart Fail, 2026, 14(2): 102441.

[33]

Ho CY, Olivotto I, Jacoby D, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy[J].Circ Heart Fail, 2020, 13(6): e006853.

[34]

Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation, 2020, 142(25): e533-557.

[35]

彭娟, 范琳琳, 李然宜, 等. 心力衰竭药物治疗的研究进展[J].中国临床药理学与治疗学, 2022, 27(4): 373-381.

[36]

Hegde SM, Wang X, Garcia-Pavia P, et al. Effect of aficamten compared with metoprolol on echocardiographic measures in symptomatic obstructive hypertrophic cardiomyopathy: MAPLE-HCM[J].J Am Coll Cardiol, 2025, 86(24): 2452-2467.

基金资助

国家自然科学基金重点项目(82430016)

2026 年度上海市教育科学研究项目(C2026063)

AI Summary AI Mindmap
PDF (1307KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉